These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 33524928)

  • 21. Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up.
    Hersh CM; Love TE; Cohn S; Hara-Cleaver C; Bermel RA; Fox RJ; Cohen JA; Ontaneda D
    Mult Scler Relat Disord; 2016 Nov; 10():44-52. PubMed ID: 27919497
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Three-Year Effectiveness of Dimethyl Fumarate in Multiple Sclerosis: A Prospective Multicenter Real-World Study.
    Pilo de la Fuente B; Sabín J; Galán V; Thuissard I; Sainz de la Maza S; Costa-Frossard L; Gómez-Moreno M; Díaz-Díaz J; Oreja-Guevara C; Lozano-Ros A; García-Domínguez JM; Borrego L; Ayuso L; Castro A; Sánchez P; Meca-Lallana V; Muñoz C; Casanova I; López de Silanes C; Martín H; Rodríguez-García E; Andreu-Vázquez C; Blasco R; García-Merino JA; Aladro Y;
    CNS Drugs; 2020 Dec; 34(12):1275-1286. PubMed ID: 33226562
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lower lymphocyte counts and older age are associated with reduced multiple sclerosis disease activity during dimethyl fumarate treatment.
    Garbo R; Lorenzut S; Del Negro I; Merlino G; Gigli GL; Cargnelutti D; Valente M
    Mult Scler Relat Disord; 2021 Apr; 49():102781. PubMed ID: 33524927
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunological Predictors of Dimethyl Fumarate-Induced Lymphopenia.
    Diebold M; Galli E; Kopf A; Sanderson N; Callegari I; Ingelfinger F; Núñez NG; Benkert P; Kappos L; Kuhle J; Becher B; Claassen M; Derfuss T
    Ann Neurol; 2022 May; 91(5):676-681. PubMed ID: 35170072
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dimethyl fumarate and teriflunomide for multiple sclerosis in a real-life setting: a French retrospective cohort study.
    Condé S; Moisset X; Pereira B; Zuel M; Colamarino R; Maillet-Vioud M; Lauxerois M; Taithe F; Clavelou P;
    Eur J Neurol; 2019 Mar; 26(3):460-467. PubMed ID: 30320947
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dimethyl fumarate: a possible exit strategy from natalizumab treatment in patients with multiple sclerosis at risk for severe adverse events.
    Calabrese M; Pitteri M; Farina G; Bajrami A; Castellaro M; Magliozzi R; Monaco S
    J Neurol Neurosurg Psychiatry; 2017 Dec; 88(12):1073-1078. PubMed ID: 28844068
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-life use of oral disease-modifying treatments in Austria.
    Guger M; Enzinger C; Leutmezer F; Kraus J; Kalcher S; Kvas E; Berger T;
    Acta Neurol Scand; 2019 Jul; 140(1):32-39. PubMed ID: 30958901
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of dimethyl fumarate in multiple sclerosis: a multi-center observational study.
    Miclea A; Leussink VI; Hartung HP; Gold R; Hoepner R
    J Neurol; 2016 Aug; 263(8):1626-32. PubMed ID: 27260297
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The budget impact of introducing delayed-release dimethyl fumarate for treatment of relapse-remitting multiple sclerosis in Canada.
    Dorman E; Kansal AR; Sarda S
    J Med Econ; 2015; 18(12):1085-91. PubMed ID: 26390149
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY).
    Cohan SL; Moses H; Calkwood J; Tornatore C; LaGanke C; Smoot KE; Meka V; Okwuokenye M; Hotermans C; Mendoza JP; Mann MK; Meltzer LA
    Mult Scler Relat Disord; 2018 May; 22():27-34. PubMed ID: 29524759
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-life persistence and tolerability with dimethyl fumarate.
    Sejbaek T; Nybo M; Petersen T; Illes Z
    Mult Scler Relat Disord; 2018 Aug; 24():42-46. PubMed ID: 29906666
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative effectiveness of teriflunomide and dimethyl fumarate in patients with relapsing forms of MS in the retrospective real-world Teri-RADAR study.
    Zivadinov R; Kresa-Reahl K; Weinstock-Guttman B; Edwards K; Burudpakdee C; Bergsland N; Dwyer MG; Khatri B; Thangavelu K; Chavin J; Mandel M; Cohan S
    J Comp Eff Res; 2019 Apr; 8(5):305-316. PubMed ID: 30754997
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England.
    Maruszczak MJ; Montgomery SM; Griffiths MJ; Bergvall N; Adlard N
    J Med Econ; 2015; 18(11):874-85. PubMed ID: 26055952
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience.
    D'Amico E; Zanghì A; Sciandra M; Borriello G; Callari G; Gallo A; Salemi G; Cottone S; Buccafusca M; Valentino P; Bossio RB; Grimaldi LME; Pozzilli C; Tedeschi G; Zappia M; Patti F
    J Neurol; 2019 Feb; 266(2):411-416. PubMed ID: 30515629
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Persistence with dimethyl fumarate in relapsing-remitting multiple sclerosis: a population-based cohort study.
    Eriksson I; Cars T; Piehl F; Malmström RE; Wettermark B; von Euler M
    Eur J Clin Pharmacol; 2018 Feb; 74(2):219-226. PubMed ID: 29128972
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Meta-analysis of adverse events in recent randomized clinical trials for dimethyl fumarate, glatiramer acetate and teriflunomide for the treatment of relapsing forms of multiple sclerosis.
    Zagmutt FJ; Carroll CA
    Int J Neurosci; 2015; 125(11):798-807. PubMed ID: 25387069
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relapsing-Remitting Multiple Sclerosis Is Characterized by a T Follicular Cell Pro-Inflammatory Shift, Reverted by Dimethyl Fumarate Treatment.
    Cunill V; Massot M; Clemente A; Calles C; Andreu V; Núñez V; López-Gómez A; Díaz RM; Jiménez MLR; Pons J; Vives-Bauzà C; Ferrer JM
    Front Immunol; 2018; 9():1097. PubMed ID: 29896193
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Delayed lymphocyte re-population following discontinuation of dimethyl fumarate and after switching to other disease modifying drug therapies.
    Khatri BO; Tarima SS; Essig B; Sesing J; Olapo T
    Mult Scler Relat Disord; 2017 Nov; 18():60-64. PubMed ID: 29141823
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis.
    Freedman MS; Montalban X; Miller AE; Dive-Pouletty C; Hass S; Thangavelu K; Leist TP
    Mult Scler Relat Disord; 2016 Nov; 10():204-212. PubMed ID: 27919491
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dimethyl fumarate-associated transient bone marrow oedema syndrome.
    Triplett J; Vijayan S; Prince R; Kermode A
    Mult Scler; 2019 May; 25(6):876-879. PubMed ID: 30051766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.